AAV9-HEXA/HEXB gene therapy (Axovant Sciences)

N/A

Report date: 2025/01/26 18:11:29

Base Information

Drug NameAAV9-HEXA/HEXB gene therapy (Axovant Sciences)
Drug Alias NameAAV9- HEXA/HEXB gene therapy(Axovant Gene Therapies)AAV9- beta-hexosaminidase alpha/beta gene therapy(Axovant Sciences)AAV9-HEXA/HEXB gene therapy (University of Massachusetts)AAV9- beta-hexosaminidase alpha/beta gene therapy (University of Massachusetts)
ClassificationBiologics
Mechanisms of ActionBeta-hexosaminidase subunit alpha gene transferenceBeta-hexosaminidase subunit beta gene transference
TargetsBeta-hexosaminidase subunit alphaBeta-hexosaminidase subunit beta
Therapy Area/IndicationsTay-Sachs DiseaseSandhoff Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Massachusetts Medical School
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of Massachusetts Medical SchoolSio Gene Therapies Inc
Inactive CompaniesN/A
Active IndicationsTay-Sachs DiseaseSandhoff Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A